Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | CHUK | O15111 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4491512 | 0.89 | IKBKB (0.31) | IKBKBSMYD3 | |
| SCHEMBL4199003 | 0.74 | BRD4 (0.36) | IKBKBCHUKENPP2SMYD3BRD4 | |
| SCHEMBL4500677 | 0.72 | HRH3 (0.31) | — | |
| SCHEMBL4515458 | 0.71 | SMYD3 (0.40) | IKBKBSMYD3 | |
| SCHEMBL2423379 | 0.71 | IKBKB (0.39) | IKBKBCHUKENPP2SMYD3BRD4 | |
| SCHEMBL960858 | 0.70 | KMT2A (0.39) | IKBKBCHUKENPP2BRD4 | |
| SCHEMBL4511202 | 0.70 | HRH3 (0.39) | IKBKBSMYD3 | |
| Hydrochloric Acid SCHEMBL2815292 | 0.69 | KMT2A (0.38) | IKBKBCHUKBRD4 | |
| SCHEMBL4506004 | 0.67 | HRH3 (0.31) | — | |
| SCHEMBL4504695 | 0.67 | PARP1 (0.38) | SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | CCNI, MKI67, CDK2 | IKBKB 172/4885CHUK 86/4885ENPP2 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.